A clinical piece for foot and limb care providers on how GLP-1 drugs relate to the lower extremity. Only the title is available.
Recap by typeshit. Full story at HMP Global Learning Network.
6:25
Dr Almerie compares Lilly's experimental retatrutide with Mounjaro and talks through the case for switching versus holding off until it's approved.
He points to GLP-1 receptors in the hypothalamus, saying the medication boosts fullness signals and slows the stomach, which changes how hunger feels.
10:08
Weight loss doctor Bazgha Khalid goes through what the published trials actually show for Zepbound against Lilly's newer retatrutide.
Patients who took a GLP-1 receptor agonist before surgery did not lose more weight at one year, JAMA Surgery reports. The full study has the details.
The doctor walks through what can happen when people come off weight loss injections, a growing question as more users consider quitting.
He describes restaurant meals feeling different on the drugs, after years of planning the whole order before even arriving.
Loading…